[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200903929B - Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor - Google Patents

Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Info

Publication number
ZA200903929B
ZA200903929B ZA200903929A ZA200903929A ZA200903929B ZA 200903929 B ZA200903929 B ZA 200903929B ZA 200903929 A ZA200903929 A ZA 200903929A ZA 200903929 A ZA200903929 A ZA 200903929A ZA 200903929 B ZA200903929 B ZA 200903929B
Authority
ZA
South Africa
Prior art keywords
dosage form
oral administration
tyrosine kinase
kinase inhibitor
pharmaceutical dosage
Prior art date
Application number
ZA200903929A
Other languages
English (en)
Inventor
Bernd Leipold
Joerg Rosenberg
Martin Knobloch
Christian Nehen
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of ZA200903929B publication Critical patent/ZA200903929B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200903929A 2006-11-09 2009-06-05 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor ZA200903929B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06023367A EP1920767A1 (en) 2006-11-09 2006-11-09 Melt-processed imatinib dosage form

Publications (1)

Publication Number Publication Date
ZA200903929B true ZA200903929B (en) 2010-03-31

Family

ID=38291110

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903929A ZA200903929B (en) 2006-11-09 2009-06-05 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Country Status (13)

Country Link
US (1) US8841303B2 (ru)
EP (2) EP1920767A1 (ru)
JP (1) JP5280369B2 (ru)
CN (3) CN102512680A (ru)
AU (1) AU2007316557B2 (ru)
BR (2) BRPI0718523B8 (ru)
CA (1) CA2668775C (ru)
ES (1) ES2565036T3 (ru)
MX (1) MX2009004858A (ru)
PL (1) PL2086516T3 (ru)
RU (1) RU2468788C2 (ru)
WO (1) WO2008055965A1 (ru)
ZA (1) ZA200903929B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
JP6032616B2 (ja) 2011-08-04 2016-11-30 国立研究開発法人国立がん研究センター Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
EA026665B1 (ru) 2011-11-24 2017-05-31 Имунекс Фарма Илак Санайи Ве Тикарет А.С. Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
CA2860973C (en) 2012-01-13 2021-10-26 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CN106074554A (zh) * 2015-04-27 2016-11-09 陈骏英 一种用于治疗食管癌的药物及使用方法
CN104888228A (zh) * 2015-05-29 2015-09-09 连云港杰瑞药业有限公司 一种甲苯磺酸索拉非尼固体分散体及其制备方法
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
CN106974890A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种无定型舒尼替尼l-苹果酸盐与药用辅料的固体分散体及其制备方法
EP3429589B1 (en) * 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Pharmaceutical composition of nilotinib
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CA3155855A1 (en) * 2020-12-07 2022-06-07 Tianjin Creatron Biotechnology Co., Ltd. Sorafenib pharmaceutical composition with high bioavailability and use thereof
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384661A (en) * 1982-04-07 1983-05-24 Page Edward H Aerosol water-based paint compositions
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO1999051208A1 (en) * 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
EA006402B1 (ru) * 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
RU2231015C1 (ru) * 2002-10-03 2004-06-20 Федеральное Государственное унитарное предприятие "Государственное научно-производственное предприятие "Сплав" Устройство угловой стабилизации реактивного снаряда
CA2509958A1 (en) * 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
NZ543614A (en) * 2003-05-22 2009-09-25 Abbott Lab Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form

Also Published As

Publication number Publication date
EP1920767A1 (en) 2008-05-14
AU2007316557A1 (en) 2008-05-15
RU2009121653A (ru) 2010-12-20
RU2468788C2 (ru) 2012-12-10
AU2007316557B2 (en) 2013-10-31
CN101594852B (zh) 2013-04-03
CA2668775C (en) 2014-08-12
US8841303B2 (en) 2014-09-23
CN101594851B (zh) 2013-01-02
EP2086516B1 (en) 2016-01-06
JP5280369B2 (ja) 2013-09-04
CN101594851A (zh) 2009-12-02
PL2086516T3 (pl) 2016-08-31
EP2086516A1 (en) 2009-08-12
BRPI0718521A2 (pt) 2013-11-19
CN102512680A (zh) 2012-06-27
ES2565036T3 (es) 2016-03-30
BRPI0718523B1 (pt) 2022-03-03
US20100240672A1 (en) 2010-09-23
WO2008055965A1 (en) 2008-05-15
BRPI0718523A2 (pt) 2013-11-19
CN101594852A (zh) 2009-12-02
MX2009004858A (es) 2009-05-21
CA2668775A1 (en) 2008-05-15
BRPI0718523B8 (pt) 2022-09-13
JP2010509288A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
ZA200903929B (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
IL193727A0 (en) Dosage forms for administering combinations of drugs
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
HK1220902A1 (zh) 族群抑制劑之口服醫藥劑型
IL206159A0 (en) Oral pharmaceutical dosage forms
PL2384754T3 (pl) Farmaceutyczne postacie dawkowania
IL179456A0 (en) Dosage form for delivery of multiple drug forms
ZA200900345B (en) Preparation of pharmaceutical formulations
DK2099406T3 (da) Opbevarings- og udleveringsindretninger til administration af oralt transmucosale doseringsformer
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
EP2062579A4 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING OPTICALLY STABLE RAMOSETRON
HK1206267A1 (en) Stabilized picoplatin oral dosage form
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
ITMI20061741A1 (it) Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
GB0610207D0 (en) New forms of active pharmaceutical ingredient
ZA200806439B (en) Stable dosage formulations of imidazolylalkyl-pyridines